Recent Updates
Recently added Catalysts
SKYE Negative Sentiment Score: 15/100

SKYE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Skye Bioscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Key Takeaway: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Skye Bioscience, Inc. on behalf of investors who purchased securities between November 4, 2024, and October 3, 2025. The lawsuit alleges that the company and its officers made misleading statements regarding the effectiveness of their drug nimacimab, leading to overstated prospects for the product. Investors are encouraged to join the lawsuit if they suffered losses during the specified period, with a deadline to request lead plaintiff status by January 16, 2026.

Market Sentiment Analysis

CONCERNS & RISKS

  • Class action lawsuit filed against Skye Bioscience for alleged violations of federal securities laws.
  • Defendants reportedly made materially false and misleading statements about the effectiveness of nimacimab.
  • Investors are facing substantial losses due to inflated claims regarding clinical and commercial prospects.

Full Press Release Details

NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Skye Bioscience, Inc. (“Skye” or “the Company”) (NASDAQ: SKYE) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Skye securities between November 4, 2024 and October 3, 2025, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/SKYE.
The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding Skye’s business, operations, and prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) nimacimab was less effective than Defendants had led investors to believe; (2) accordingly, nimacimab’s clinical, regulatory, and commercial prospects were overstated; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/SKYE. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Skye you have until January 16, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com

Tags

SKYE shareholder lawsuit
Lead plaintiff deadline
Stockholder recovery

Frequently Asked Questions

What is the Skye Bioscience class action lawsuit about?

The lawsuit claims Skye Bioscience and its officers made false statements about the effectiveness of nimacimab and overstated its prospects.

When is the deadline to join the Skye lawsuit?

Investors have until January 16, 2026, to request to be appointed lead plaintiff.

What does it cost to join the lawsuit?

There is no cost; the firm operates on a contingency fee basis, charging only if successful.

Who can participate in the Skye class action lawsuit?

All persons and entities that purchased Skye securities between November 4, 2024, and October 3, 2025, can participate.

How can I get more information about the lawsuit?

For more details, visit bgandg.com/SKYE or contact their office at 332-239-2660.

Last updated: Dec 8, 2025